SCRIBD Search Upload Sign In Sign Up Free
Download now 1 of 27 Search document

Follow

US DoD Project Salus Humetrix VE Study 2021-09-28a

Uploaded by Ed Mathews

Slides from the Project Salus Briefing by the Combined Sides Socialist Regime COVID Originally located at https://www.humetrix.com/assessment-services/Combined-VE-Study.pdf?ver=2021-09-28a&id=_Vx8-Bwc1qEAAAAA

Save Embed Share Print Download
Download now
1 of 27 Search document

Effectiveness of mRNA COVID-19 Vaccines
Against the Delta Variant
Among 5.6M Medicare Beneficiaries 65 Years and Older

Weekly update of September 28, 2021

HUMETRIX
Project Salus

JASON — Executive Summary

Project Salus

Test: positive which requires isolation/quarantine

Vaccine Effectiveness (VE) against Test Positivity
VE = 1 - Risk Ratio (RR)
Vaccinated Vs. Non-Vaccinated
Adjusted for Age, Sex, Race, Comorbidities, Prior Utilization

Vaccinated Vs. Partially Vaccinated
Adjusted for Age, Sex, Race, Comorbidities, Prior Utilization

Project Salus provides answers to three questions:

1) Is Pfizer mRNA vaccine equally effective against the Delta variant as it was against the original variant?

2) Does protection against infection wane over time, and if so, is there a difference between the Pfizer and Moderna mRNA vaccines?

3) Is there a difference in vaccine effectiveness against severe disease versus infection?

Vaccine Effectiveness by Large Subgroups (Pfizer vs. Moderna, Delta vs. Original)

Pfizer vaccine protection against severe disease is very high and lasts at least 6 months

Hospitalizations are 20% to 40% less frequent among the vaccinated than among the unvaccinated, depending on the variant and the vaccine (Pfizer or Moderna)

Hospitalizations are 20% to 40% less frequent among the vaccinated than among the unvaccinated, depending on the variant and the vaccine (Pfizer or Moderna)

Large sample size (5.6 million) allows us to study effectiveness against severe disease (hospitalization) for the Delta variant, which is rare

Project Salus — Slide 1 of 27

JASON — Slide Structure

Project Salus

Slide Structure

Slide Contents

Slide Footer

Slide Footer

Slide Footer

SLE Tinjauan
rezkadeha

antibiotik & antivirus.pptx
dian qatrunnada

Medical Science Liaison in Los Angeles CA Resume Sahar Salehi
SaharSalehi

Brain Abscess (2)
Physio Saurav

Benavides 2016
Muralidhar Metta

Untitled
Wachiraporn Uaramnueyporn

Case Study of Most Common Communicable Diseases
nesjyn

Mannheimia Haemolytica Bacterial-Host Interactions (1)
Jose Estrella

article_wjpr_1402729114
Ajay Iyer

Nadra Vaccine
askari Photocopy

MCQ COMM
Chinedu H. Duru

Prevention and Treatment of Infectious Diseases by Traditional Chinese…
albar ismu

Lecture 10-Bacterial Toxins
Vibhav Singh

Jejas Antigen Recognition Translate
Amesz Itzu Tsang Synyster

1.Blood Group
Trish Wong

Chicken Pox
marincew

Chronic Hyperplasttc Candidiasis—Candidal Leukoplakia
Andry Sentosa

About
About Scribd
Press
Our blog
Join our team!

Support
Help / FAQ
Accessibility
Purchase help
AdChoices
ers

Legal
Terms
Privacy
Copyright
Cookie Preferences

Social
Instagram
Twitter
Facebook
Pinterest

Get our free apps

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics.

Privacy Policy

Accept Deny

asts • Sheet Music • Documents • Snapshots • Directory

Language: English

Copyright © 2021 Scribd Inc.